ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.55
1.45%
US Tech 100
20,148.80
0.11%
S&P 500
5,948.71
0.53%
US Dollar vs CAD
1.39839
0.03%
Bitcoin
98,839.30
0.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) News

Ascendis Pharma AS

Ascendis Pharma AS (ASND)

ASN Duurzaam Aandelenfonds Inc
Ascendant Resources Inc
122.64
-1.74
(-1.40%)
Closed November 22 3:00PM
Delayed by 15 minutes
122.64
-0.265
(-0.22%)
After Hours: 6:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

ASND News

Official News Only

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
November 19 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 14 2024
ASND (-1.40%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
ASND (-1.40%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 13 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 04 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 09 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 30 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 27 2024
ASND (-1.40%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
September 23 2024
ASND (-1.40%)

ASND Discussion

View Posts
Monksdream Monksdream 9 months ago
ASND new 52=week high
👍️0
Monksdream Monksdream 9 months ago
ASND new 52 week high
👍️0
MiamiGent MiamiGent 9 months ago
What goes down, must go up :)
Hope you banked, monk.
👍️0
Monksdream Monksdream 9 months ago
ASND new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ASND new 52 week high
👍️0
MiamiGent MiamiGent 2 years ago
ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish
👍️0
MiamiGent MiamiGent 2 years ago
ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE
👍️0
MiamiGent MiamiGent 2 years ago
$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish
👍️0
MiamiGent MiamiGent 2 years ago
ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.
👍️0
MiamiGent MiamiGent 2 years ago
ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND
👍️0
MiamiGent MiamiGent 2 years ago
Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$
👍️0
crudeoil24 crudeoil24 3 years ago
Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
👍️0
crudeoil24 crudeoil24 3 years ago

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
👍️0

Your Recent History

NASDAQ
ASND
Ascendis Pharma AS
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved